Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 16/20 | 0.39 |
| ▸ | PDE2A | O00408 | 1/20 | 0.39 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.39 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18306688 | 0.90 | ADAM17 (0.34) | CHRM1PDE2APDE11AADAM17NPC1 | |
| SCHEMBL12072183 | 0.85 | NPC1 (0.41) | CHRM1NPC1ALDH1A1HPGDTSHR | |
| SCHEMBL14839936 | 0.80 | CHRM1 (0.43) | CHRM1PDE2APDE11AADAM17NPC1 | |
| SCHEMBL23698892 | 0.77 | CHRM1 (0.36) | CHRM1PDE2APDE11A | |
| SCHEMBL12803106 | 0.77 | CHRM1 (0.42) | CHRM1 | |
| SCHEMBL14848411 | 0.74 | CHRM1 (0.55) | CHRM1PDE2APDE11AADAM17 | |
| SCHEMBL23698954 | 0.72 | CHRM1 (0.39) | CHRM1 | |
| SCHEMBL23712085 | 0.72 | CHRM1 (0.36) | CHRM1 | |
| SCHEMBL18725422 | 0.71 | CNR1 (0.47) | CHRM1PDE2APDE11AGABRA1 | |
| SCHEMBL18725418 | 0.71 | CNR1 (0.47) | CHRM1PDE2APDE11AGABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2582676-B1 | TETRAHYDROQUINOLINE AMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2016-12-14 | — | — | EP | disclosed |
| EP-2582676-B1 | TETRAHYDROQUINOLINE AMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2016-12-14 | — | — | EP | disclosed |
| US-8815902-B2 | Tetrahydroquinoline amide M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2014-08-26 | — | — | US | disclosed |
| US-8815902-B2 | Tetrahydroquinoline amide M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2014-08-26 | — | — | US | disclosed |
| US-8815902-B2 | Tetrahydroquinoline amide M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2014-08-26 | — | — | US | disclosed |
| US-20130090352-A1 | TETRAHYDROQUINOLINE AMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2013-04-11 | — | — | US | disclosed |
| US-20130090352-A1 | TETRAHYDROQUINOLINE AMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2013-04-11 | — | — | US | disclosed |
| US-20130090352-A1 | TETRAHYDROQUINOLINE AMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2013-04-11 | — | — | US | disclosed |
| WO-2011159554-A1 | TETRAHYDROQUINOLINE AMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2011-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090352-A1 | TETRAHYDROQUINOLINE AMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, OPRL1, OPRM1 | CHRM1 1/4885PDE2A 1068/4885PDE11A 1701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.